| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/07/2013 | US20130034578 Recombinant multimeric influenza proteins |
| 02/07/2013 | US20130034577 Methods and Compositions for Vaccination Comprising Nucleic Acid and/or Polypeptide Sequences of Chlamydia |
| 02/07/2013 | US20130034576 Novel adenovirus isolated from titi monkeys |
| 02/07/2013 | US20130034575 Method for identification, isolation and production of antigens to a specific pathogen |
| 02/07/2013 | US20130034574 Modified melk peptides and vaccines containing the same |
| 02/07/2013 | US20130034573 Vaccine compositions |
| 02/07/2013 | US20130034572 Compositions and methods for brain delivery of analgesic peptides |
| 02/07/2013 | US20130034571 Methods for inducing in vivo tolerance |
| 02/07/2013 | US20130034570 Methods and compositions for modulating prostasin |
| 02/07/2013 | US20130034569 Il-18 receptor antigen binding proteins |
| 02/07/2013 | US20130034568 Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| 02/07/2013 | US20130034567 Protein modulators |
| 02/07/2013 | US20130034566 Anti-cdh3 antibodies and uses thereof |
| 02/07/2013 | US20130034565 MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES |
| 02/07/2013 | US20130034564 Anti-rsv g protein antibodies |
| 02/07/2013 | US20130034563 Use for production of therapeutic agent or prophylactic agent for osteoarthritis |
| 02/07/2013 | US20130034562 Selective androgen receptor modulators for treating diabetes |
| 02/07/2013 | US20130034561 Isolated mammalian monocyte cell genes; related reagents |
| 02/07/2013 | US20130034560 Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same |
| 02/07/2013 | US20130034559 Targeted Binding Agents Against B7-H1 |
| 02/07/2013 | US20130034558 Epidermal growth factor receptor variant |
| 02/07/2013 | US20130034557 Cancer-Related Glycopeptide Epitopes, Antibodies And Methods Of Use |
| 02/07/2013 | US20130034556 Free hexasaccharide isolated from several campylobacter species |
| 02/07/2013 | US20130034555 Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases |
| 02/07/2013 | US20130034554 Antibodies to il-6 and use thereof |
| 02/07/2013 | US20130034553 Fusion Polypeptides Capable of Activating Receptors |
| 02/07/2013 | US20130034552 Temperature sensitive conjugate compositions, and uses related thereto |
| 02/07/2013 | US20130034551 Wnt Antagonists and Methods of Treatment and Screening |
| 02/07/2013 | US20130034550 Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| 02/07/2013 | US20130034549 Combination therapy for treating breast cancer |
| 02/07/2013 | US20130034548 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| 02/07/2013 | US20130034547 Reliable stabilization of n-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns |
| 02/07/2013 | US20130034546 Analyzing Copy Number Variation in the Detection of Cancer |
| 02/07/2013 | US20130034545 Treatment of traumatic brain injury using antibodies to lysophosphatidic acid |
| 02/07/2013 | US20130034544 Methods for treating, diagnosing, and monitoring lupus |
| 02/07/2013 | US20130034543 Modulating xrn1 |
| 02/07/2013 | US20130034542 Cold treatment |
| 02/07/2013 | US20130034541 Pharmaceutical compositions |
| 02/07/2013 | US20130034540 Immune Gene Signatures in Cancer |
| 02/07/2013 | US20130034539 Sr-bi as a predictor of human female infertility and responsiveness to treatment |
| 02/07/2013 | US20130034538 Reverse hexagonal mesophases (hii) and uses thereof |
| 02/07/2013 | US20130034500 Cationic Steroid Antimicrobial Compositions and Methods of Use |
| 02/07/2013 | US20130034493 Methods and compositions for modulation of olfml3 mediated angiogenesis |
| 02/07/2013 | US20130034492 Class I Anti-CEA Antibodies and Uses Thereof |
| 02/07/2013 | CA2844042A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| 02/07/2013 | CA2844040A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| 02/07/2013 | CA2844038A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| 02/07/2013 | CA2844037A1 Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
| 02/07/2013 | CA2844034A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| 02/07/2013 | CA2844030A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| 02/07/2013 | CA2843804A1 Hypoallergenic variants of mal d 1, the major allergen from malus domestica |
| 02/07/2013 | CA2843636A1 Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject |
| 02/07/2013 | CA2843595A1 Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| 02/07/2013 | CA2843535A1 Treatment of heart failure and related conditions |
| 02/07/2013 | CA2843386A1 Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct |
| 02/07/2013 | CA2843315A1 Bovine polyclonal antibody specific for human tnf |
| 02/07/2013 | CA2843274A1 Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
| 02/07/2013 | CA2842872A1 Recombinant swine influenza virus and uses thereof |
| 02/07/2013 | CA2842432A1 Method for treating bone gap defects |
| 02/07/2013 | CA2842368A1 Switch costimulatory receptors |
| 02/06/2013 | EP2554552A1 Novel anti-cd98 antibody and use thereof |
| 02/06/2013 | EP2553150A1 Generation of antibodies to an epitope of interest |
| 02/06/2013 | EP2553096A1 Ect2 peptides and vaccines including the same |
| 02/06/2013 | EP2552966A1 Antibodies against csf-1r |
| 02/06/2013 | EP2552965A2 Anti-cd40 antibodies |
| 02/06/2013 | EP2552964A1 CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY |
| 02/06/2013 | EP2552963A1 Humanized anti cxcr4 antibodies for the treatment of cancer |
| 02/06/2013 | EP2552961A1 Humanized il-25 antibodies |
| 02/06/2013 | EP2552959A2 Antibodies to muc16 and methods of use thereof |
| 02/06/2013 | EP2552958A2 Monoclonal antibody directed against the p17 protein of hiv, capable of neutralising the binding of p17 to the p17 receptor (p17r) |
| 02/06/2013 | EP2552957A1 Antibodies with enhanced or suppressed effector function |
| 02/06/2013 | EP2552947A2 Vista regulatory t cell mediator protein, vista binding agents and use thereof |
| 02/06/2013 | EP2552944A1 Compositions and methods for the removal of biofilms |
| 02/06/2013 | EP2552942A1 Factor h binding proteins (fhbp) with altered properties and methods of use thereof |
| 02/06/2013 | EP2552490A1 Ectodomains of influenza matrix 2 protein, expression system, and uses thereof |
| 02/06/2013 | EP2552489A1 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant |
| 02/06/2013 | EP2552485A1 Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament |
| 02/06/2013 | EP2552484A1 Methods and compositions for reducing parathyroid levels |
| 02/06/2013 | EP2552483A1 Antibody-based depletion of antigen-presenting cells and dendritic cells |
| 02/06/2013 | EP2552482A2 Stabilized antibody preparations and uses thereof |
| 02/06/2013 | EP2552481A1 Bispecific antibodies |
| 02/06/2013 | EP2552480A1 Hiv vaccine |
| 02/06/2013 | EP2552479A1 Influenza virus vaccines and uses thereof |
| 02/06/2013 | EP2552478A1 Excipients for stabilising viral particles, polypeptides or biological material |
| 02/06/2013 | EP2552477A2 Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae |
| 02/06/2013 | EP2552476A1 Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof |
| 02/06/2013 | EP2552472A2 Anti-inflammatory factors |
| 02/06/2013 | EP2552465A1 Stabilisation of viral particles |
| 02/06/2013 | EP2552463A1 Proangiogenic compositions, method for preparing same, and uses thereof |
| 02/06/2013 | EP2552452A1 Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer |
| 02/06/2013 | EP2552451A1 Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and tumor initiating cells |
| 02/06/2013 | EP2552411A2 Stabilized antibody preparations and uses thereof |
| 02/06/2013 | EP2552410A2 Method for preserving alum adjuvants and alum-adjuvanted vaccines |
| 02/06/2013 | CN102918063A Anti-cd40 antibodies |
| 02/06/2013 | CN102918062A Therapeutic methods using anti-CD200 antibodies |
| 02/06/2013 | CN102918061A Antibodies against human CSF-1R and uses thereof |
| 02/06/2013 | CN102918059A Anti-CD27 antibody |
| 02/06/2013 | CN102918053A Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same |
| 02/06/2013 | CN102917732A Immunoglobulin preparation and storage system for an immunoglobulin preparation |
| 02/06/2013 | CN102917731A Multivalent synthetic nanocarrier vaccines |